Your browser doesn't support javascript.
loading
The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension.
Newnham, Michael; South, Kieron; Bleda, Marta; Auger, William R; Barberà, Joan A; Bogaard, Harm; Bunclark, Katherine; Cannon, John E; Delcroix, Marion; Hadinnapola, Charaka; Howard, Luke S; Jenkins, David; Mayer, Eckhard; Ng, Choo; Rhodes, Christopher J; Screaton, Nicholas; Sheares, Karen; Simpson, Michael A; Southwood, Mark; Su, Li; Taboada, Dolores; Traylor, Matthew; Trembath, Richard C; Villar, Sofia S; Wilkins, Martin R; Wharton, John; Gräf, Stefan; Pepke-Zaba, Joanna; Laffan, Michael; Lane, David A; Morrell, Nicholas W; Toshner, Mark.
Afiliação
  • Newnham M; Dept of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • South K; Royal Papworth Hospital, Cambridge, UK.
  • Bleda M; Centre for Haematology, Imperial College London, London, UK.
  • Auger WR; Dept of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Barberà JA; University of California, San Diego, CA, USA.
  • Bogaard H; Hospital Clínic - IDIBAPS-CIBER Enfermedades Respiratorias, University of Barcelona, Barcelona, Spain.
  • Bunclark K; VU University Medical Centre, Amsterdam, The Netherlands.
  • Cannon JE; Royal Papworth Hospital, Cambridge, UK.
  • Delcroix M; Royal Papworth Hospital, Cambridge, UK.
  • Hadinnapola C; KU Leuven - University of Leuven, Leuven, Belgium.
  • Howard LS; Dept of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Jenkins D; Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • Mayer E; Royal Papworth Hospital, Cambridge, UK.
  • Ng C; Kerckhoff Heart and Lung Centre, Bad Nauheim, Germany.
  • Rhodes CJ; Royal Papworth Hospital, Cambridge, UK.
  • Screaton N; Centre for Pharmacology and Therapeutics, Dept of Medicine, Hammersmith Campus, Imperial College London, London, UK.
  • Sheares K; Royal Papworth Hospital, Cambridge, UK.
  • Simpson MA; Royal Papworth Hospital, Cambridge, UK.
  • Southwood M; Dept of Medical and Molecular Genetics, King's College London School of Basic and Medical Biosciences, London, UK.
  • Su L; Royal Papworth Hospital, Cambridge, UK.
  • Taboada D; MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
  • Traylor M; Royal Papworth Hospital, Cambridge, UK.
  • Trembath RC; Dept of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
  • Villar SS; Dept of Medical and Molecular Genetics, King's College London School of Basic and Medical Biosciences, London, UK.
  • Wilkins MR; MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
  • Wharton J; Centre for Pharmacology and Therapeutics, Dept of Medicine, Hammersmith Campus, Imperial College London, London, UK.
  • Gräf S; Centre for Pharmacology and Therapeutics, Dept of Medicine, Hammersmith Campus, Imperial College London, London, UK.
  • Pepke-Zaba J; Dept of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Laffan M; Dept of Haematology, National Health Service Blood and Transplant Centre, University of Cambridge, Cambridge, UK.
  • Lane DA; National Institute of Health Research BioResource for Translational Research, Cambridge Biomedical Campus, Cambridge, UK.
  • Morrell NW; Royal Papworth Hospital, Cambridge, UK.
  • Toshner M; Centre for Haematology, Imperial College London, London, UK.
Eur Respir J ; 53(3)2019 03.
Article em En | MEDLINE | ID: mdl-30655285
ABSTRACT
Chronic thromboembolic pulmonary hypertension (CTEPH) is an important consequence of pulmonary embolism that is associated with abnormalities in haemostasis. We investigated the ADAMTS13-von Willebrand factor (VWF) axis in CTEPH, including its relationship with disease severity, inflammation, ABO groups and ADAMTS13 genetic variants.ADAMTS13 and VWF plasma antigen levels were measured in patients with CTEPH (n=208), chronic thromboembolic disease without pulmonary hypertension (CTED) (n=35), resolved pulmonary embolism (n=28), idiopathic pulmonary arterial hypertension (n=30) and healthy controls (n=68). CTEPH genetic ABO associations and protein quantitative trait loci were investigated. ADAMTS13-VWF axis abnormalities were assessed in CTEPH and healthy control subsets by measuring ADAMTS13 activity, D-dimers and VWF multimeric size.Patients with CTEPH had decreased ADAMTS13 (adjusted ß -23.4%, 95% CI -30.9- -15.1%, p<0.001) and increased VWF levels (ß +75.5%, 95% CI 44.8-113%, p<0.001) compared to healthy controls. ADAMTS13 levels remained low after reversal of pulmonary hypertension by pulmonary endarterectomy surgery and were equally reduced in CTED. We identified a genetic variant near the ADAMTS13 gene associated with ADAMTS13 protein that accounted for ∼8% of the variation in levels.The ADAMTS13-VWF axis is dysregulated in CTEPH. This is unrelated to pulmonary hypertension, disease severity or markers of systemic inflammation and implicates the ADAMTS13-VWF axis in CTEPH pathobiology.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Embolia Pulmonar / Fator de von Willebrand / Proteína ADAMTS13 / Hipertensão Pulmonar Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur Respir J Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Embolia Pulmonar / Fator de von Willebrand / Proteína ADAMTS13 / Hipertensão Pulmonar Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur Respir J Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Reino Unido